research News

Jerusalem, Israel – Professor Asaf Hellman and his research team at the Hebrew University-Hadassah Medical School have unveiled new findings in the realm of methylation-directed regulatory networks. Their study sheds light on the mechanisms governing the activation and suppression of mutation-driven disease genes, particularly in cases like glioblastoma, offering insights...
Tokyo, Japan – Autism spectrum disorder (ASD) is a complex neuropsychiatric condition, marked by diverse cognitive and sensorimotor challenges, difficulties with social communication, and distinct behavioral patterns. While genetic factors are known to play a role, the intricate mechanisms driving this condition remain elusive. Moreover, a unified and comprehensive theoretical...
Memphis, Tenn –  Compared to adult cancers, pediatric cancers often have distinctive genetic causes. This means there is an opportunity to develop pediatric-focused diagnostic strategies and treatments. Research by St. Jude Children’s Research Hospital published today in Nature Genetics clarifies the genomic landscape of pediatric acute myeloid leukemia (pAML). The...
ZURICH, Switzerland – Antiphospholipid syndrome is a systemic autoimmune disease associated with persistent antiphospholipid antibodies (aPL). It can cause thrombosis and pregnancy complications as well as non-thrombotic manifestations such as cardiac valve disease. Classification is important to help identify people to take part in research and ensures that similar disease...
Göttingen, Germany – In individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), uric acid (UA) metabolism might be involved in activation of the complement system and thus serve as a contributory factor in the disease course, according to findings from a retrospective study published in the International Journal of Molecular...
PRINCETON, N.J. — UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with MEDAC GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers. UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, is a...